报 告 人: 张素冰，Dr. Belamy Cheung
Children’s Cancer Institute, 澳大利亚
主 持 人：张超
时      间：2016年5月17日周二上午10:00-11:00
地      点：医学大楼1102 室

Biography
      Dr Belamy Cheung graduated from Sun Yat-Sen University of Medical Science, Guangzhou, China, and obtained her PhD degree at University of NSW, Australia in 2004. She was the first to show that the retinoic acid receptor beta acts as a tumour suppressor gene in neuroblastoma and predicts a more favorable outcome for neuroblastoma patients. Now she is a Project Leader and Manager of the Molecular Carcinogenesis (MC) Program at Children's Cancer Institute Australia. She is also a Senior Lecturer at University of NSW. Her research is currently focusing on drug discovery leading to the identification of small molecule inhibitors of oncogene targets. Dr Cheung plays a key role in directing research in the MC program and driving research in all 3 themes of the MC Program: the mechanisms of embryonal cancer initiation, the MYC oncogenesis, and, histone deacetylase inhibitor combination therapy in cancer. Dr Cheung has published 24 articles in the last 5 years including 12 first author or senior author publications, such as Science Translational Medicine; Nature Reviews Cancer, Oncogene and Journal of the National Cancer Institute. Dr Cheung is the Vice-President of the Australian Association for Chinese Biomedical Scientists (AACBS), and aims to promote cross-cultural links between China and Australia.

Employment and Education

2014-present , Manager & Project Leader of Children's Cancer Institute, Sydney, Australia.

2014-present, Senior Lecturer, Faculty of Medicine, University of New South Wales, Australia.

2004, Doctor of Philosophy, Faculty of Medicine, University of New South Wales, Australia.

Selected Publications

DR Carter, Cheung BB# and Marshall GM#. Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis. Molecular Oncology. 2016. # Equal corresponding authors.

DR Carter, J Murray, Cheung BB et al. Therapeutic targeting of the MYC signal by inhibition of
histone chaperone FACT in neuroblastoma. Science Translational Medicine. 2015.

Cheung BB et al. Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma. Molecular Oncology. 2015.

Marshall GM, Carter DR, Cheung BB. et al. The prenatal origins of cancer. Nature Reviews Cancer. 2014.